Histopathology case logs and second opinions: what RCPath assessors look for

Why case logs anchor histopathology applications

In most physician Portfolio Pathway applications, the evidence mix is varied: workplace-based assessments, reflective practice, audit, teaching records, multi-source feedback, and structured supervisor reports. No single evidence type dominates. Histopathology is different. The diagnostic report is the primary clinical output of a histopathologist's working day, and the case log is the record of those reports. Without a credible case log, an assessor cannot evaluate whether an applicant has the breadth and depth of reporting experience that the Histopathology Curriculum expects.

This creates a specific challenge for Portfolio Pathway applicants. Trainee histopathologists build their case logs systematically through a structured curriculum with defined rotations through sub-specialty areas. Applicants coming through the Portfolio Pathway - senior specialty doctors, specialist grade doctors, non-substantive Consultants, and internationally-trained pathologists - have often accumulated experience in a less structured way, concentrated in the areas their post demands rather than spread across the full curriculum. The task of the Portfolio Pathway application is to demonstrate that, despite the different pathway, the breadth and quality of reporting experience is equivalent to what the curriculum would have produced.

This article is a companion to the Histopathology Portfolio Pathway complete guide. That article covers the overall structure of the application: the eleven Capabilities in Practice, the FRCPath requirement, the ten-year evidence window, and the realistic timeline. This article focuses on the two most important evidence components: the case log and second opinion documentation.

What the RCPath SSG actually says

The GMC Specialty Specific Guidance for Histopathology is derived from the RCPath Histopathology 2021 Curriculum. The curriculum defines eleven Capabilities in Practice (CiPs): seven generic CiPs covering professional requirements shared across all specialties, and four specialty CiPs specific to histopathology.

The four specialty CiPs are:

• Laboratory leadership: running and contributing to a high-quality pathology service, including governance, quality assurance, and workforce development.
• The diagnostic use of laboratory services: selecting, interpreting, and applying laboratory investigations to reach accurate diagnoses across the breadth of the specialty.
• Multidisciplinary team working: contributing to MDT discussion, communicating pathological findings to clinical teams, and supporting clinical management decisions.
• Safe handling and interpretation of pathological specimens: the practical and intellectual core of histopathological practice, from specimen reception to final report.

The case log is the primary evidence vehicle for the fourth CiP, and contributes substantially to the second and third. An application with thin case log evidence will struggle to demonstrate CiP achievement in these three areas, regardless of how strong the generic evidence (audit, teaching, MSF, reflective practice) might be.

The SSG does not set a minimum case number for Portfolio Pathway applicants. What it asks for is evidence of competence equivalent to a doctor who has completed the full training programme. The case log is your mechanism for demonstrating that equivalence. Breadth across the curriculum domains, evidence of independent reporting, quality markers, and reflective engagement with complex or unusual cases are all part of that demonstration.

The ten-year evidence window

Histopathology has a longer evidence window than almost any other specialty in the Portfolio Pathway framework. The RCPath SSG accepts evidence from the last ten years, compared to the five-year window that most physician specialties operate. This is a meaningful difference: it means that a histopathologist who built substantial experience between 2016 and 2021 can still draw on that material for a 2026 application, whereas a geriatrician with equivalent experience from that period would be approaching the edge of what most assessors consider current.

The reason for the longer window is partly practical. Histopathology sub-specialty experience - particularly autopsy, frozen sections, and less common tumour types - is not evenly available across all posts in all years. A ten-year window allows applicants to demonstrate breadth that a five-year window might artificially truncate. The RCPath SSG specifically notes that a small amount of older evidence may be considered where it provides a more complete account of breadth of practice, particularly for skills less commonly performed in current day-to-day work, with autopsy cited as the explicit example.

This is not a reason to rely primarily on older evidence. Assessors want to see that your current practice is at Consultant equivalent level, and recent evidence carries more weight in demonstrating current competence. The longer window is a supplement, not a substitute. The recent evidence and the five-year rule article explains the general principles that apply even where the formal window is longer.

What to log: categories and what to document

A histopathology case log should cover four main categories, each of which maps to distinct areas of the curriculum. The balance between categories will differ depending on your post and subspecialty focus, but the log should address all four, with an honest explanation of any area where your experience is limited.

Within surgical histopathology, organ system breadth is the most important dimension for assessors. A log of 4,000 cases that is entirely gastrointestinal biopsies from a single endoscopy-heavy department is narrower than a log of 2,500 cases spread across gastrointestinal, gynaecological, dermatological, respiratory, head and neck, and urological specimens. Both might be adequate in volume terms; only one demonstrates the curriculum breadth the RCPath expects.

What to record for each case

The case log does not need to be a case-by-case list of diagnoses. What assessors need is a structured summary that demonstrates breadth, volume, and quality. At a minimum, each category entry in your summary log should record: the specimen type and organ system, the approximate number of cases in that category during your log period, whether reporting was independent or supervised, and whether you can provide quality marker data for that category.

For individual cases you choose to highlight - particularly second opinion cases, unusual diagnoses, or cases that map to specific CiPs - a more detailed entry is appropriate. The format for those is covered in the second opinions section below.

Case numbers: indicative figures and breadth

The RCPath Histopathology Curriculum's CCT learning map cites indicative figures of approximately 1,500 surgical histopathology cases and 300 non-cervical cytology cases per year of higher specialty training. These figures are training benchmarks rather than Portfolio Pathway requirements, but they give you a sense of the scale assessors will have in mind when reviewing your log.

A Portfolio Pathway applicant typically draws on several years of senior practice. A log covering five years of active reporting might therefore be expected to contain at least 5,000 to 7,500 surgical histopathology cases if practice has been full-time and varied. In reality, the numbers vary enormously depending on lab throughput, subspecialty focus, the proportion of time spent on administrative or management duties, and any periods of reduced clinical activity. The key point is that low volume requires an explanation and ideally a compensating strategy, while high volume without demonstrated breadth or quality is not by itself sufficient.

The breadth checklist below illustrates the organ system coverage that a strong log would typically demonstrate. It is not a formal RCPath requirement checklist; it is a practical aid for identifying gaps before you submit.

Where organ system coverage is limited by the nature of your post rather than a gap in your competence, address this directly. A histopathologist in a Trust with no neurosurgical service may have minimal neuropathology experience; a pathologist at a specialist cancer centre may have very limited experience of inflammatory skin conditions. Honest contextualisation of gaps is always better received than a log that implicitly pretends they do not exist.

If your breadth is genuinely thin in a curriculum-required area, consider whether a period in a different post, or a formal supernumerary attachment to a department with that subspecialty, is feasible before you apply. The Portfolio Pathway explained article covers the general principle of evidence gap remediation.

Second opinions: the histopathology-specific evidence mechanism

Second opinions are a formal quality mechanism in histopathology with no direct equivalent in most clinical specialties. When a diagnostic case is complex, unusual, or carries significant clinical consequences, it is standard practice to seek a colleague's view before finalising the report. This might be an informal conversation with a colleague in the same laboratory, a formal consultation with a subspecialty-trained colleague elsewhere in the Trust, or a referral to a national reference centre or tertiary specialist laboratory.

For Portfolio Pathway purposes, second opinion records are valuable evidence on multiple levels. They show that you understand the limits of your diagnostic certainty. They demonstrate collegial working and professional consultation. They generate documented records of your clinical reasoning process - what your working diagnosis was before seeking the opinion, and how you evaluated the advice you received. And critically, they provide an external check on your diagnostic quality that is independent and verifiable.

Three types of second opinion and what each demonstrates

There are three main types of second opinion in histopathology practice, and each carries distinct evidential value:

Internal consultation means asking a colleague within your own department or Trust to review a case. This might be a consultant colleague with relevant subspecialty expertise, a senior trainee under your supervision reviewing a slide from the opposite direction, or a departmental peer review session. Internal consultations demonstrate your day-to-day collegial working practice and your awareness of the breadth of expertise within your own laboratory. They are the most frequent type and the most straightforward to document systematically.

External specialist referral means sending a case, or representative material from a case, to a pathologist at a different institution with recognised specialist expertise. This is appropriate for rare tumour types, diagnostically ambiguous cases, or situations where the clinical stakes are high and local expertise is insufficient. External referrals demonstrate your engagement with the national pathology network and your commitment to diagnostic accuracy even when it requires additional time and effort.

National reference laboratory referral means sending material to a recognised national centre - for example, the UK Reference Centre for Rare Tumours at the Christie, or national sarcoma or lymphoma reference services. These referrals are appropriate for cases that exceed the diagnostic capacity of most district general hospitals, and they generate documentation from a nationally recognised expert, which carries significant evidential weight.

The three outcomes illustrated - confirmed, refined, and changed - are all legitimate portfolio entries and none is inherently better than another from an evidential standpoint. A portfolio that shows only confirmed opinions looks selective. A portfolio that includes cases where your initial diagnosis was refined or changed demonstrates exactly the self-awareness and quality orientation the GMC's Good Medical Practice 2024 framework expects.

How many second opinion records to include

There is no fixed requirement. A realistic target is ten to twenty well-documented cases across your log period, weighted towards the more diagnostically significant consultations rather than routine internal queries. A set of twenty brief, formulaic entries adds little; ten detailed records covering a range of specimen types, consultation routes, and diagnostic outcomes is substantially more persuasive. Quality of documentation matters more than quantity of entries.

What each record should contain

At minimum, each second opinion entry should include: the clinical context and specimen type (anonymised); your working diagnosis before seeking the opinion; the nature of the consultation (internal, external, national); the consulting colleague's view; the final diagnosis; the outcome for clinical management; and a brief reflection on what the case demonstrated about your practice or your learning. Three to five sentences of reflection is sufficient. The aim is to show that you engaged with the consultation intellectually, not just administratively.

Cancer minimum datasets and standardised reporting

The Royal College of Pathologists publishes minimum datasets for the reporting of all major cancer types. These datasets specify the mandatory and recommended elements that should appear in every cancer pathology report: tumour type, grade, stage parameters, margin status, lymphovascular invasion, and other tumour-specific fields that clinical teams and cancer registries require. The datasets are the standard reporting framework across NHS pathology services.

For Portfolio Pathway purposes, adherence to cancer minimum datasets is a quality marker that assessors understand immediately. A histopathologist whose cancer reports consistently contain all mandatory dataset elements, presented in the correct proforma format, is demonstrating professional standard practice that can be verified from the reports themselves.

How to demonstrate this in your portfolio:

• Include two or three anonymised exemplar reports, one from each of the main cancer types you encounter (for example, colorectal, prostate, and breast), formatted to the relevant RCPath dataset. These demonstrate your reporting standard more directly than a claim that you follow the datasets.
• If your laboratory has conducted an audit of dataset completion rates, include your personal figure and the departmental benchmark. A dataset completion rate above 95% for mandatory elements, drawn from your LIMS data, is a strong quality indicator.
• If your department participates in national cancer dataset quality assurance, include the relevant summary. NHS England and the major cancer networks periodically audit dataset completion as part of the National Cancer Patient Experience Programme and related initiatives.

The RCPath cancer minimum datasets are freely available on the RCPath website. There are separate datasets for over thirty tumour types. Knowing which datasets apply to the cancer types in your log is a basic professional competency; including references to the relevant datasets in your portfolio entries demonstrates awareness of current standards.

MDT participation as portfolio evidence

Multidisciplinary team working is one of the four specialty CiPs in the Histopathology curriculum, and it occupies a larger role in histopathology practice than it does in most laboratory specialties. Histopathologists attend tumour boards, present diagnostic findings, advise on the clinical significance of pathological features, and contribute to treatment planning discussions. This is not peripheral activity; it is how the diagnostic output of a pathology laboratory connects to patient care.

For Portfolio Pathway evidence, MDT participation needs to be documented specifically as portfolio material, not simply listed as a job plan activity. The following forms of MDT evidence carry most weight:

Regular attendance records confirm that you have been an active member of one or more MDTs throughout your log period. A log showing your attendance at a named MDT - tumour site, frequency, and your role - is the basic documentation. Ask your MDT coordinator for a letter confirming your participation if formal records exist.

Direct Observation of MDT Performance or equivalent assessments, where a senior colleague or MDT chair observes your contribution and provides a structured assessment, maps directly to the CiP requirement. If your department does not use a formal DOMP tool, a structured supervisor's report that addresses your MDT role specifically is an acceptable alternative.

Reflective entries on specific MDT discussions are the most powerful MDT evidence. A reflection describing a case where your pathological findings were central to a management decision - where the histological subtype determined the chemotherapy protocol, where the margin assessment influenced the decision about re-excision, where your frozen section result changed the operative approach - demonstrates the clinical impact of histopathological practice in a way that attendance records cannot.

For a histopathologist in a cancer centre, MDT evidence is likely to be abundant. For a district general hospital histopathologist covering multiple tumour sites at a less intensive frequency, the approach should be the same - quality of reflection over quantity of meetings attended. The workplace-based assessments article covers the general framework for DOPS and structured assessments that apply to MDT participation evidence as well as procedural skills.

Overseas case logs: what assessors expect

Histopathologists who have built the majority of their experience outside the UK face a specific challenge. The RCPath assesses whether a Portfolio Pathway applicant can function as a Consultant histopathologist within the NHS. That means reporting to RCPath minimum dataset standards, contributing to NHS cancer pathways, working within NHS governance and quality assurance frameworks, and participating in UK MDT culture. A case log from an overseas institution demonstrates diagnostic experience, but it does not by itself demonstrate readiness to operate within those specific NHS frameworks.

The honest picture for doctors applying directly from overseas without any UK histopathology experience is that the evidential gap is significant and the deferral rate is high. Most assessors will want to see some UK practice before recommending entry to the Specialist Register. A period as a specialist grade or locum histopathologist within an NHS Trust, even of twelve to eighteen months, allows you to generate UK-verified case material, UK EQA data, UK MDT records, and a UK supervisor reference - all of which address the specific gaps in an overseas-only application. The article on translating overseas evidence for the Portfolio Pathway covers the broader principles that apply across specialties.

Quality markers beyond case volume

A strong histopathology Portfolio Pathway application includes quality evidence that goes beyond what the case log itself can demonstrate. Case numbers and organ system breadth show what you have reported; quality markers show how well you reported it. The most credible quality data is independently verified - it comes from systems and processes outside your own record-keeping.

The four main quality marker categories to consider are:

Turnaround times: The RCPath and NHS England publish guidelines on cancer reporting turnaround times. For urgent cancer specimens, the RCPath standard is a final report within five working days in over 90% of cases. Your LIMS can generate personal TAT data. Present this as a table showing your TAT distribution against the published standard, with a brief reflection on any periods where performance dipped and what caused it.

EQA participation: UK NEQAS for Cellular Pathology circulates cases to participating laboratories and individual pathologists for assessment. Your EQA performance - specifically your personal scores on circulated cases - provides independent, verified evidence of diagnostic accuracy across a range of specimen types. If you are not currently participating in EQA schemes relevant to your practice, enrolling through your Trust's quality lead before your application strengthens your evidence base materially. Check the UK NEQAS website for the relevant cellular pathology modules.

Peer review discordance: Many NHS laboratories run peer review programmes where a proportion of cases are reviewed by a second pathologist without knowledge of the original report. The rate at which your diagnoses differ from the peer reviewer's - particularly the major discordance rate - is a quality indicator. The RCPath peer review guidance defines major discordance as a difference that would change clinical management. A major discordance rate below 1% is a strong quality indicator. Include your personal data from any peer review programme your Trust operates.

Audit of reporting quality: An audit against a published RCPath dataset, measuring your department's compliance with mandatory reporting elements, is both a quality improvement piece (relevant to the audit evidence guidance) and a quality marker that speaks directly to your reporting standards. If you have led or contributed to such an audit, cross-reference it explicitly in your quality markers section.

Packaging for submission

The quality of the evidence you generate is only part of what assessors evaluate. The other part is how legibly you present it. An assessor reviewing multiple applications in a single sitting will form an impression of your portfolio's organisation within the first few minutes, and that impression shapes how they read everything that follows. A well-structured submission makes it easy to reach a positive conclusion; a disorganised one creates work for the assessor and doubt in their mind.

The case log section should have a clear index. A cover sheet listing the documents contained, the log period covered, and the total case volumes by category allows an assessor to navigate directly to the evidence they need. Without an index, assessors must read through the entire submission to locate specific evidence types - which increases the risk that something is overlooked.

The reflective practice attached to the case log is what transforms a transaction record into portfolio evidence. A case log without reflection says "I reported many cases." A case log with reflection says "I understood what I was doing, I engaged with complexity, and I developed as a practitioner." The reflective practice writing article covers the principles in detail. Applied to histopathology, the key is to select cases that demonstrate clinical reasoning and professional judgement, not just technical competence in common specimen types.

Before opening your GMC Online application window, review the current GMC Online application walkthrough and the Portfolio Pathway costs and fees guide to understand the full application mechanics. The case log preparation described above is the most time-consuming element of a histopathology application; allow several months to assemble and organise it before you start the clock on the 24-month application window.

All 18 specialisms

This article is part of the histopathology evidence cluster. Every specialism with a live Portfolio Pathway overview is linked below. Histopathology is the parent specialism for this deep-dive.

Read this article alongside the histopathology overview and the general evidence guides it cross-references. The next-sequence below follows the most logical reading path for a histopathology applicant building their portfolio.